Product Description: Vipivotide tetraxetan (PSMA-617) is a high potent prostate-specific membrane antigen (PSMA) inhibitor, with a Ki of 0.37 nM. Vipivotide tetraxetan (PSMA-617) is designed consisting of three components: the pharmacophore Glutamate-urea-Lysine, the chelator DOTA able to complex both 68Ga or 177Lu, and a linker connecting these two entities. Glutamate-urea-Lysine is the selective pharmacophore to bind to prostate specific membrane antigen.
Applications: Cancer-programmed cell death
Formula: C49H71N9O16
References: [1]Benešová M, et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. J Nucl Med. 2015 Jun;56(6):914-20.
CAS Number: 1702967-37-0
Molecular Weight: 1042.14
Compound Purity: 99.57
Research Area: Cancer
Solubility: DMSO : 125 mg/mL (ultrasonic)/H2O : ≥ 100 mg/mL
Target: Drug-Linker Conjugates for ADC
English
Deutsch
